PL3684359T3 - Antagoniści TRPV2 - Google Patents
Antagoniści TRPV2Info
- Publication number
- PL3684359T3 PL3684359T3 PL18855917.3T PL18855917T PL3684359T3 PL 3684359 T3 PL3684359 T3 PL 3684359T3 PL 18855917 T PL18855917 T PL 18855917T PL 3684359 T3 PL3684359 T3 PL 3684359T3
- Authority
- PL
- Poland
- Prior art keywords
- trpv2
- antagonists
- trpv2 antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1715008.7A GB201715008D0 (en) | 2017-09-18 | 2017-09-18 | TRPV2 Antagonists |
| PCT/PT2018/050035 WO2019054891A2 (en) | 2017-09-18 | 2018-09-14 | ANTAGONISTS OF TRPV2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3684359T3 true PL3684359T3 (pl) | 2025-06-09 |
Family
ID=60159402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18855917.3T PL3684359T3 (pl) | 2017-09-18 | 2018-09-14 | Antagoniści TRPV2 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11273152B2 (pl) |
| EP (1) | EP3684359B1 (pl) |
| JP (1) | JP7255785B2 (pl) |
| CN (1) | CN111315382A (pl) |
| AU (1) | AU2018332608B2 (pl) |
| BR (1) | BR112020005408A2 (pl) |
| CA (1) | CA3075981A1 (pl) |
| EA (1) | EA202090786A1 (pl) |
| ES (1) | ES3015419T3 (pl) |
| GB (1) | GB201715008D0 (pl) |
| HR (1) | HRP20250405T1 (pl) |
| HU (1) | HUE071054T2 (pl) |
| PL (1) | PL3684359T3 (pl) |
| RS (1) | RS66698B1 (pl) |
| SG (1) | SG11202002207QA (pl) |
| SM (1) | SMT202500261T1 (pl) |
| WO (1) | WO2019054891A2 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201715008D0 (en) * | 2017-09-18 | 2017-11-01 | Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa | TRPV2 Antagonists |
| RS65944B1 (sr) * | 2020-05-22 | 2024-10-31 | Philogen Spa | Terapija tnf-a imunokonjugatom za lečenje tumora mozga |
| CN112266352B (zh) * | 2020-11-20 | 2022-02-08 | 绍兴文理学院 | 一种荜茇酰胺衍生物及其制备方法和用途 |
| WO2024033372A1 (en) * | 2022-08-09 | 2024-02-15 | Instituto de Medicina Molecular João Lobo Antunes | Antiviral compound |
| WO2024054462A1 (en) * | 2022-09-05 | 2024-03-14 | Gbs Global Biopharma, Inc. | Phytochemical formulations for treating stress and anxiety |
| WO2025125509A1 (en) * | 2023-12-12 | 2025-06-19 | Targtex S.A. | Chemotherapeutic agent and compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU213200B (en) * | 1993-05-12 | 1997-03-28 | Chinoin Gyogyszer Es Vegyeszet | The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production |
| CA2718400A1 (en) * | 2008-03-11 | 2009-09-17 | The General Hospital Corporation | Piperlongumine and piperlongumine analogs for use in the treatment of cancer |
| KR20120104165A (ko) | 2009-09-02 | 2012-09-20 | 매사추세츠 제네럴 호스피털 코퍼레이션 | 암 치료용 화합물 및 조성물 |
| CN102146054A (zh) * | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
| CN104415035A (zh) * | 2013-08-19 | 2015-03-18 | 江苏靶标生物医药研究所有限公司 | 荜茇酰胺在制备抗肿瘤转移药物中的运用 |
| EP3156497A1 (en) * | 2015-10-16 | 2017-04-19 | Centre National de la Recherche Scientifique (C.N.R.S.) | Trpv2 as a biomarker and as a therapeutic target for melanoma |
| GB201715008D0 (en) * | 2017-09-18 | 2017-11-01 | Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa | TRPV2 Antagonists |
-
2017
- 2017-09-18 GB GBGB1715008.7A patent/GB201715008D0/en not_active Ceased
-
2018
- 2018-09-14 BR BR112020005408-9A patent/BR112020005408A2/pt unknown
- 2018-09-14 EA EA202090786A patent/EA202090786A1/ru unknown
- 2018-09-14 US US16/647,995 patent/US11273152B2/en active Active
- 2018-09-14 CA CA3075981A patent/CA3075981A1/en active Pending
- 2018-09-14 JP JP2020515907A patent/JP7255785B2/ja active Active
- 2018-09-14 PL PL18855917.3T patent/PL3684359T3/pl unknown
- 2018-09-14 RS RS20250355A patent/RS66698B1/sr unknown
- 2018-09-14 CN CN201880071896.9A patent/CN111315382A/zh active Pending
- 2018-09-14 SM SM20250261T patent/SMT202500261T1/it unknown
- 2018-09-14 HR HRP20250405TT patent/HRP20250405T1/hr unknown
- 2018-09-14 HU HUE18855917A patent/HUE071054T2/hu unknown
- 2018-09-14 AU AU2018332608A patent/AU2018332608B2/en active Active
- 2018-09-14 WO PCT/PT2018/050035 patent/WO2019054891A2/en not_active Ceased
- 2018-09-14 SG SG11202002207QA patent/SG11202002207QA/en unknown
- 2018-09-14 ES ES18855917T patent/ES3015419T3/es active Active
- 2018-09-14 EP EP18855917.3A patent/EP3684359B1/en active Active
-
2022
- 2022-02-01 US US17/590,061 patent/US12370185B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE071054T2 (hu) | 2025-07-28 |
| GB201715008D0 (en) | 2017-11-01 |
| WO2019054891A3 (en) | 2019-10-24 |
| JP7255785B2 (ja) | 2023-04-11 |
| US20200253943A1 (en) | 2020-08-13 |
| EP3684359C0 (en) | 2025-02-12 |
| JP2020535125A (ja) | 2020-12-03 |
| US11273152B2 (en) | 2022-03-15 |
| BR112020005408A2 (pt) | 2020-09-29 |
| AU2018332608B2 (en) | 2023-10-12 |
| HRP20250405T1 (hr) | 2025-05-23 |
| AU2018332608A1 (en) | 2020-04-16 |
| CA3075981A1 (en) | 2019-03-21 |
| EP3684359B1 (en) | 2025-02-12 |
| WO2019054891A2 (en) | 2019-03-21 |
| US12370185B2 (en) | 2025-07-29 |
| SG11202002207QA (en) | 2020-04-29 |
| US20220152006A1 (en) | 2022-05-19 |
| ES3015419T3 (en) | 2025-05-05 |
| EA202090786A1 (ru) | 2020-07-01 |
| SMT202500261T1 (it) | 2025-09-12 |
| CN111315382A (zh) | 2020-06-19 |
| RS66698B1 (sr) | 2025-05-30 |
| EP3684359A2 (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201806632B (en) | Soluble c5ar antagonists | |
| SI3666771T1 (sl) | LPA antagonisti | |
| SMT202100561T1 (it) | Antagonisti di trpv4 | |
| GB201717974D0 (en) | Modified receptors | |
| IL258892B (en) | Calcitonin gene-related peptide receptor antagonists | |
| SG11202002207QA (en) | Trpv2 antagonists | |
| ZA202001147B (en) | Construction component | |
| IL256496B (en) | 5–ht2 blockers | |
| IL274751A (en) | ILDR2 antagonists and combinations thereof | |
| IL258893A (en) | Cgrp receptor antagonists | |
| IL267686A (en) | Integrin antagonists | |
| IL256572A (en) | cgrp receptor antagonists | |
| GB201815629D0 (en) | Antagonists | |
| IL258894A (en) | Cgrp receptor antagonists | |
| SG11202105784WA (en) | Antagonists | |
| ZA201807767B (en) | Angiotensin-1-receptor antagonists | |
| PT3464324T (pt) | Antagonistas de recetores da angiotensina-1 |